Alterity Therapeutics Limited
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Alterity Therapeutics Limited is a clinical-stage biopharmaceutical company primarily engaged in the research, development, and commercialization of novel therapeutics for neurodegenerative diseases. The company focuses on developing treatments for Parkinson's disease and other central nervous system disorders. Its core products and services include drug candidates targeting mitochondrial dysfunction and oxidative stress pathways, with lead clinical programs centered on ATH-1017 (for neurodegenerative treatment) and ATH-1020 (aimed at Parkinson's disease-related symptoms). Alterity Therapeutics also conducts preclinical research and development in related therapeutic areas. The company operates mainly in Australia and North America. Founded in 2004 and headquartered in Sydney, Australia, Alterity Therapeutics has recently undergone strategic shifts, including advancing ATH-1017 into late-stage clinical trials and expanding its pipeline to address various neurological conditions. In the past 1-2 years, the company has strengthened its research collaborations and investor base, with new funding rounds supporting clinical development progress. It has also positioned itself to leverage cutting-edge scientific approaches to address unmet needs in chronic neurodegenerative diseases. Alterity Therapeutics operates within the biotechnology sector, targeting healthcare providers, pharmaceutical partners, and research institutions as its primary market. The company is listed under the ticker symbol ATHE. Its evolving portfolio reflects a commitment to developing innovative therapies that improve patient outcomes globally, particularly in markets across Australia, the United States, and Europe. No recent name changes or acquisitions were prominently noted to have occurred within the last two years. This detailed description captures Alterity Therapeutics' business activities, product focus, recent developments, and market positioning based on the latest available information.
Company News
Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference
Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson's Disease and Movement Disorders
Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Stock Has Average Price Target of $10.00
Alterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026
Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434
Alterity Therapeutics to Present at the 46th Annual Canaccord Genuity Growth Conference
Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update
Alterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026
Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy
Alterity Therapeutics Advances Lead Drug Towards Pivotal Study For Rare Neuromuscular Disorder
Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy
Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy
Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy
Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026
Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update
Alterity Therapeutics Limited (ATHE) Discusses Phase II Data and Development Strategy for ATH434 in Multiple System Atrophy Transcript
Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy
Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology
Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors
Head to Head Contrast: NovoCure (NASDAQ:NVCR) versus Alterity Therapeutics (NASDAQ:ATHE)